KCM
MRNA icon

Kathmere Capital Management’s Moderna MRNA Stock Holding History

Kathmere Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50
Closed -$5K – 301
2020
Q4 		$5K Hold
50
– – ﹤0.01% 348
2020
Q3 		$4K Buy
+50
New +$3.49K ﹤0.01% 337

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Kathmere Capital Management's MRNA Position: Q1 2021 in Review

Kathmere Capital Management sold out of Moderna (MRNA) in Q1 2021, closing a stake of 50 shares — an estimated $5K sold.

Kathmere Capital Management first reported a position in MRNA in Q3 2020 and held it in 2 quarters. The position peaked at $5K in Q4 2020. 776 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

  • Kathmere Capital Management reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
  • Kathmere Capital Management sold 50 Moderna shares in Q1 2021, an estimated $5K.
  • Kathmere Capital Management first reported a position in Moderna in Q3 2020 and held it in 2 quarters.
  • Kathmere Capital Management's Moderna position peaked at $5K in Q4 2020.
  • 776 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Kathmere Capital Management's 13F filing for Q1 2021, filed 7 May 2021.